891 related articles for article (PubMed ID: 24355485)
41. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer.
Fakkert IE; Abma EM; Westrik IG; Lefrandt JD; Wolffenbuttel BH; Oosterwijk JC; Slart RH; van der Veer E; de Bock GH; Mourits MJ
Eur J Cancer; 2015 Feb; 51(3):400-8. PubMed ID: 25532426
[TBL] [Abstract][Full Text] [Related]
42. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
[TBL] [Abstract][Full Text] [Related]
43. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
[TBL] [Abstract][Full Text] [Related]
44. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.
Morgan D; Sylvester H; Lucas FL; Miesfeldt S
Fam Cancer; 2009; 8(4):277-87. PubMed ID: 19347608
[TBL] [Abstract][Full Text] [Related]
45. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
Powell CB; Chen LM; McLennan J; Crawford B; Zaloudek C; Rabban JT; Moore DH; Ziegler J
Int J Gynecol Cancer; 2011 Jul; 21(5):846-51. PubMed ID: 21670699
[TBL] [Abstract][Full Text] [Related]
46. Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.
Julian-Reynier C; Mancini J; Mouret-Fourme E; Gauthier-Villars M; Bonadona V; Berthet P; Fricker JP; Caron O; Luporsi E; Noguès C
Eur J Hum Genet; 2011 May; 19(5):500-6. PubMed ID: 21267012
[TBL] [Abstract][Full Text] [Related]
47. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
Powell CB; Kenley E; Chen LM; Crawford B; McLennan J; Zaloudek C; Komaromy M; Beattie M; Ziegler J
J Clin Oncol; 2005 Jan; 23(1):127-32. PubMed ID: 15625367
[TBL] [Abstract][Full Text] [Related]
48. Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
Solsky I; Chen J; Rebbeck TR
Gynecol Oncol; 2020 Feb; 156(2):363-376. PubMed ID: 31918993
[TBL] [Abstract][Full Text] [Related]
49. A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.
Loizzi V; Cicinelli E; Del Vecchio V; Arezzo F; Deromemaj X; Kardhashi A; Paradiso A; Legge F; Natalicchio MI; Resta L; Resta N; Loconte DC; Cormio G
Acta Biomed; 2022 Aug; 93(4):e2022051. PubMed ID: 36043985
[TBL] [Abstract][Full Text] [Related]
50. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Arai M; Iwase T; Takazawa Y; Takeshima N
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
[TBL] [Abstract][Full Text] [Related]
52. Breast cancer after bilateral risk-reducing mastectomy.
Skytte AB; Crüger D; Gerster M; Laenkholm AV; Lang C; Brøndum-Nielsen K; Andersen MK; Sunde L; Kølvraa S; Gerdes AM
Clin Genet; 2011 May; 79(5):431-7. PubMed ID: 21199491
[TBL] [Abstract][Full Text] [Related]
53. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
[TBL] [Abstract][Full Text] [Related]
54. A survey of preventive measures among BRCA1 mutation carriers from Poland.
Gronwald J; Byrski T; Huzarski T; Cybulski C; Stawicka M; Szwiec M; Debniak T; Tulman A; Sun P; Oszurek O; Lubinski J; Narod SA
Clin Genet; 2007 Feb; 71(2):153-7. PubMed ID: 17250664
[TBL] [Abstract][Full Text] [Related]
55. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
56. Uptake and efficacy of bilateral risk reducing surgery in unaffected female
Marcinkute R; Woodward ER; Gandhi A; Howell S; Crosbie EJ; Wissely J; Harvey J; Highton L; Murphy J; Holland C; Edmondson R; Clayton R; Barr L; Harkness EF; Howell A; Lalloo F; Evans DG
J Med Genet; 2022 Feb; 59(2):133-140. PubMed ID: 33568438
[TBL] [Abstract][Full Text] [Related]
57. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
Chai X; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Tung N; Weitzel JN; Couch FJ; Hulick PJ; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Blum JL; Domchek SM; Chen J; Rebbeck TR
Breast Cancer Res Treat; 2014 Nov; 148(2):397-406. PubMed ID: 25311111
[TBL] [Abstract][Full Text] [Related]
58. Risk-reducing salpingo-oophorectomy for BRCA mutation carriers.
Haldar K; Crawford R
Maturitas; 2010 Nov; 67(3):290. PubMed ID: 20869823
[No Abstract] [Full Text] [Related]
59. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
[TBL] [Abstract][Full Text] [Related]
60. Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations.
Garcia C; Lyon L; Littell RD; Powell CB
Genet Med; 2014 Dec; 16(12):896-902. PubMed ID: 24854227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
